Alexander Glunz

Genentech, a Member of the Roche Group

Alexander (Alex) Glunz obtained his M. Sc. (Dipl.Ing.) in Pharmaceutical Technology and
Industrial Engineering at University Albstadt-Sigmaringen, Germany in 2003. Alex started his
career in the Biotech Industry with Vetter-Pharma GmbH in Ravensburg, Germany. Starting
in Quality Assurance, Alex moved quickly into Aseptic Production where he managed the
production department at a state-of-the-art sterile production site. In 2011, Alex relocated to
the United States where he worked in multiple managerial roles for Genentech Inc. at their
plant in Hillsboro, OR. During his tenure, Alex led the implementation and start-up of sterile
compounding and filling systems at the Hillsboro-site. After successfully completing an
assignment to introduce a high speed lyophilization filling line for F. Hoffmann-La Roche Ltd
in Mannheim, Germany he accepted an assignment to establish next generation aseptic
filling capabilities for individualized therapies in Genentech’s iNEST Program in Hillsboro,
USA and Mainz, Germany.
As of 2019, Alex works as Global Program Lead for Emerging Technologies for F.
Hoffmann-La Roche Ltd, implementing a standardized fleet-concept for modular drug
product systems worldwide.


Appearances

  • Thumbnail for Cell and Gene Therapy Product Manufacturing
    Date
    June 10, 2020
    With the significant progression of late stage cell and gene therapy products, and the market approval of personal therapies, manufacturing of these complex products requires advanced technologies. With the reality of no inventory (e.g…

    Speakers

    Speaker Image for Alexander Glunz
    Genentech, a Member of the Roche Group
    Speaker Image for Patrick Chen
    Sangamo Therapeutics, Inc.
    Speaker Image for Thomas Finn
    CBER, FDA